Eton Pharmaceuticals (ETON) News Today $18.90 -0.02 (-0.11%) Closing price 04:00 PM EasternExtended Trading$19.22 +0.32 (+1.67%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why is Eton Pharmaceuticals Down Today?Eton Pharmaceuticals, Inc. (NASDAQ:ETON) shares have risen on upbeat analyst forecasts and a key U.S. FDA approval, driving renewed investor interest. U.S. FDA approved Khindivi (hydrocortisone) oral solution for pediatric adrenocortical insufficiency, potentially boosting 2025 revenue. HC Wainwright raised its Q3 2025 EPS estimate to $0.14 (from $0.13), reiterated a Buy rating and set a $35 price target, projecting continued earnings growth into 2026. Shares gapped up on heavy volume as the market digested the FDA nod and analyst upgrade. Posted 4h agoAI Generated. May Contain Errors. ETON Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period FDA approves Eton’s application for hydrocortisone oral solutionMay 30 at 11:00 PM | msn.comEton Pharmaceuticals (NASDAQ:ETON) Shares Gap Up - Here's WhyEton Pharmaceuticals (NASDAQ:ETON) Shares Gap Up - What's Next?May 30 at 10:32 AM | marketbeat.comEton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI (hydrocortisone) Oral SolutionMay 30 at 5:41 AM | finanznachrichten.deNorthern Trust Corp Purchases 22,827 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Northern Trust Corp boosted its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 35.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,957 shares of the company's stock afterMay 30 at 3:04 AM | marketbeat.comEton Pharmaceuticals stock rises on FDA approval of KHINDIVIMay 29 at 7:40 PM | investing.comEton Pharmaceuticals Gains on FDA Green Light for Pediatric Drug KHINDIVIMay 29 at 7:40 PM | msn.comEton Pharma wins FDA nod for oral hydrocortisone solutionMay 29 at 7:40 PM | msn.comFDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 RevenueMay 29 at 1:20 PM | benzinga.comEton Pharmaceuticals, Inc. (ETON) Launches Game-Changer for Adrenal InsufficiencyMay 29 at 12:57 AM | insidermonkey.comEton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral SolutionMay 28 at 5:28 PM | globenewswire.comJane Street Group LLC Has $857,000 Stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Jane Street Group LLC grew its holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 328.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,323 shares of the company's stock after buyMay 26, 2025 | marketbeat.comParadigm Capital Management Inc. NY Sells 100,000 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Paradigm Capital Management Inc. NY decreased its holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 33.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 200,000 shares of the company's stock after selMay 22, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Buys New Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)OMERS ADMINISTRATION Corp purchased a new position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 37,900 shares of the company's stock, valued at approximaMay 21, 2025 | marketbeat.comEton Pharmaceuticals Set To Dominate Orphan Drug NicheMay 21, 2025 | seekingalpha.comQ3 EPS Estimates for Eton Pharmaceuticals Cut by B. RileyEton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities research analysts at B. Riley lowered their Q3 2025 earnings estimates for Eton Pharmaceuticals in a report issued on Thursday, May 15th. B. Riley analyst M. El-Saadi now expects that the company will post earnings per share of $0.May 20, 2025 | marketbeat.comB. Riley Issues Pessimistic Forecast for ETON EarningsMay 20, 2025 | americanbankingnews.comCubist Systematic Strategies LLC Grows Stock Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Cubist Systematic Strategies LLC lifted its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 422.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 43,239 shares of the company's stock afterMay 18, 2025 | marketbeat.comParkman Healthcare Partners LLC Grows Stock Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Parkman Healthcare Partners LLC increased its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 6.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 276,890 shares of the company's stock afterMay 16, 2025 | marketbeat.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comMink Brook Asset Management LLC Takes $6.07 Million Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Mink Brook Asset Management LLC acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 455,805 shares of the company's stock, valued at approximately $6,071,000. Eton PharmaMay 15, 2025 | marketbeat.comEton Pharmaceuticals to Participate at Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comA Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 AnalystsMay 14, 2025 | benzinga.comQ1 2025 Eton Pharmaceuticals Inc Earnings CallMay 14, 2025 | finance.yahoo.comEton outlines path to $100M near-term revenue with ET-400 launch and Increlex growthMay 13, 2025 | msn.comEton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comEton Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comZevra Therapeutics's Earnings OutlookMay 12, 2025 | benzinga.comA Look Ahead: Eton Pharmaceuticals's Earnings ForecastMay 12, 2025 | benzinga.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Bought by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC lifted its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 421.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,664 shares of the company's stock after buyinMay 10, 2025 | marketbeat.comEnvestnet Asset Management Inc. Invests $236,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Envestnet Asset Management Inc. acquired a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,740 shares ofMay 10, 2025 | marketbeat.comBarclays PLC Takes Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Barclays PLC acquired a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 54,886 shares of the company's stocMay 9, 2025 | marketbeat.com7EYPT : A Peek at EyePoint Pharmaceuticals's Future EarningsMay 6, 2025 | benzinga.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Purchased by Marshall Wace LLPMarshall Wace LLP grew its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 75.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 36,182 shares of the company's stock after purchasing an additionMay 5, 2025 | marketbeat.com683 Capital Management LLC Purchases New Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)683 Capital Management LLC acquired a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 69,000 shares of the company's stMay 4, 2025 | marketbeat.comEton Pharmaceuticals (ETON) to Release Quarterly Earnings on ThursdayEton Pharmaceuticals (NASDAQ:ETON) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-eton-pharmaceuticals-inc-stock/)May 3, 2025 | marketbeat.comQ1 EPS Estimate for Eton Pharmaceuticals Lifted by AnalystEton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities research analysts at B. Riley lifted their Q1 2025 earnings estimates for Eton Pharmaceuticals in a research note issued on Sunday, April 27th. B. Riley analyst M. El-Saadi now expects that the company will earn $0.13 per share forMay 2, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires 51,238 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)JPMorgan Chase & Co. raised its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 7,086.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 51,961 shares of the company's stock after buying an addMay 2, 2025 | marketbeat.comEton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025May 1, 2025 | globenewswire.comB. Riley Lifts Earnings Estimates for Eton PharmaceuticalsEton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities researchers at B. Riley upped their Q4 2025 earnings per share estimates for Eton Pharmaceuticals in a report released on Sunday, April 27th. B. Riley analyst M. El-Saadi now forecasts that the company will post earnings of $0.33 pMay 1, 2025 | marketbeat.comNantahala Capital Management LLC Grows Stock Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Nantahala Capital Management LLC boosted its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 12.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,118,483 shares of the company's stock after acquiring an additional 119,750 shares during tApril 30, 2025 | marketbeat.comEton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)April 28, 2025 | globenewswire.com24,710 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Bought by Jump Financial LLCJump Financial LLC acquired a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 24,710 shares of the company's stock, valued at approximately $329,000.April 28, 2025 | marketbeat.comRenaissance Technologies LLC Has $2.57 Million Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Renaissance Technologies LLC grew its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 131.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 193,100 shares of the company's stock after bApril 27, 2025 | marketbeat.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest UpdateEton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 343,900 shares, a growth of 46.0% from the March 15th total of 235,600 shares. Based on an average trading volume of 287,400 shares, the short-interest ratio is presently 1.2 days. Currently, 1.6% of the company's shares are short sold.April 20, 2025 | marketbeat.comEAM Investors LLC Decreases Stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)EAM Investors LLC trimmed its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 25.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 95,019 shares of the company's stock after selling 33,257 shares during the periodApril 19, 2025 | marketbeat.comB.Riley Financial Remains a Buy on Eton Pharmaceuticals (ETON)April 17, 2025 | markets.businessinsider.comEton Pharmaceuticals management to meet virtually with B. RileyApril 12, 2025 | markets.businessinsider.comEton Pharmaceuticals management to meet with Craig HallumApril 10, 2025 | markets.businessinsider.comCannell Capital LLC Purchases New Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Cannell Capital LLC bought a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 381,323 shares of the company's stock, valued at approximatelyApril 10, 2025 | marketbeat.comAristides Capital LLC Grows Stock Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Aristides Capital LLC raised its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 20.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 241,587 shares of the company's stocApril 8, 2025 | marketbeat.com Get Eton Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter. Email Address ETON Media Mentions By Week ETON Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ETON News Sentiment▼1.150.87▲Average Medical News Sentiment ETON News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ETON Articles This Week▼134▲ETON Articles Average Week Get Eton Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARWR News VCEL News KNSA News HRMY News DNLI News BLTE News CGON News NAMS News KYMR News GLPG News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ETON) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHISTORIC Gold Move Sends Flashing Red Signal To 401K SaversHistorically, when panic hits Wall Street, investors rush to raise cash to cover their leveraged positions be ...Colonial Metals | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.